We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Adding Ketamine to Low Dose Bupivacaine in Saddle Block for Perianal Surgery

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: August 29, 2017
Last Update Posted: August 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Esam Eldin Mohamed Abdalla, Assiut University
Evaluation of the anesthetic quality and analgesic efficacy of adding ketamine to intrathecal bupivavaine in selective saddle block for perianal surgery.

Condition Intervention Phase
Perianal Fistula Hemorrhoids Drug: Ketamine Drug: bupivacaine Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: Adding Ketamine to Low Dose Bupivacaine in Saddle Block for Perianal Surgery

Resource links provided by NLM:

Further study details as provided by Esam Eldin Mohamed Abdalla, Assiut University:

Primary Outcome Measures:
  • - Duration of saddle block [ Time Frame: 24 hours post-operative ]
    (time from intrathecal injection to the time of first complain of pain, first request for analgesia, or a reported NRS >4)

Secondary Outcome Measures:
  • Evaluation of the need of supplemental analgesia [ Time Frame: 24 hours post-operative ]
    time of 1st dose

Enrollment: 60
Actual Study Start Date: January 1, 2017
Estimated Study Completion Date: December 31, 2017
Estimated Primary Completion Date: October 31, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: The ketamine group
The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
Drug: Ketamine
an antagonist of the NMDA receptor
Other Name: ketalar
Drug: bupivacaine
local anaesthetic
Other Name: marcaine 0.5 %
Placebo Comparator: The control group
group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
Drug: bupivacaine
local anaesthetic
Other Name: marcaine 0.5 %

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects will be included in the study only if they meet all of the following criteria:
  • Patients scheduled for perianal surgeries.
  • Age 18-55 years.
  • ASA physical status I-II.

Exclusion Criteria:

  • Subjects will be excluded from the study for any of the following reasons:
  • Patient refusal
  • Any contraindication of regional anaesthesia
  • Failed Technique
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Esam Eldin Mohamed Abdalla, Clinical Professor, Assiut University
ClinicalTrials.gov Identifier: NCT03264430     History of Changes
Other Study ID Numbers: 17100219
First Submitted: May 29, 2017
First Posted: August 29, 2017
Last Update Posted: August 30, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Esam Eldin Mohamed Abdalla, Assiut University:
Perianal fistula

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action